4//SEC Filing
Ratliff John D 4
Accession 0001127602-18-005993
CIK 0000920148other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 2:25 PM ET
Size
7.9 KB
Accession
0001127602-18-005993
Insider Transaction Report
Form 4
Ratliff John D
CEO, Covance Drug Development
Transactions
- Award
Non-qualified Stock Options
2018-02-12+17,100→ 17,100 totalExercise: $168.49From: 2019-02-12Exp: 2028-02-11→ Common Stock (17,100 underlying) - Award
Restricted Stock Unit
2018-02-12+4,390→ 14,217 total→ Common Stock (4,390 underlying)
Footnotes (5)
- [F1]Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- [F2]The option vests in three equal installments beginning on the date reflected in this column.
- [F3]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F4]The Restricted Stock Units vest in three equal annual installments beginning on 2/12/19.
- [F5]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
Documents
Issuer
LABORATORY CORP OF AMERICA HOLDINGS
CIK 0000920148
Entity typeother
Related Parties
1- filerCIK 0001575951
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 2:25 PM ET
- Size
- 7.9 KB